Marcus Lind

Professor/ Chief Physician

Telephone

Mail

About Marcus Lind

Marcus Lind presented his thesis in year 2009 at the University of Gothenburg focusing on evaluating effects of modern insulin analogues and HbA1c as a risk factor for diabetic complications. During his post-doc period he performed work at the Mid-America Heart Institute, Missouri University, US. Besides his research he has worked clinical as chief physician of Diabetology at the NU (NÄL and Uddevalla)-Hospital Group. He became Associate Professor of Diabetology year 2014 at the University of Gothenburg. He has performed essential research both in the epidemiologic field and clinical randomized trials which have been presented in New England Journal of Medicine, Lancet, JAMA and British Medical Journal. He has been in charge of over 40 studies.

Honors and Awards:

The Erik K Fernströms award 2019 which is awarded 1 researcher each year at each university in Sweden. Awarded by Lund University.

The Jubilee Prize at the 200 year anniversary of the Gothenburg Society for Physicians which was awarded to two physicians at the University of Gothenburg among all disciplines.

The Jubilee Prize year 2017 awarded one physician in Sweden among all disciplines. Awarded by the Society of Physicians in Sweden.

Prize from Dr P Håkanssons Foundation for studies of diet in diabetes year 2017.

National prize 2012 from Swedish Society for Diabetology (SFD) for best diabetic publication in Sweden in 2011 regarding Heart Failure in Persons with Type 1 Diabetes. (Lind. M., Lancet, June, 2011)

Prize as the “Diabetologist of the year” in Sweden in 2009 for research of metabolic memory and diabetic complications in the DCCT study.

Prize for good scientific methodology and presentation at the "National meeting for physicians in Sweden in 2006”.

Text books

Main editor for the text book “Medicinska Sjukdomar”. A text book in internal medicine of approximately 800 pages comprising the different fields in internal medicine. Author of the diabetes and endocrinology chapters. Released by “Studentlitteratur” year 2020.

Author in the text book “Diabetes” released by “Studentlitteratur” year 2020, comprising approximately 500 pages.

Main research

Dr Marcus Lind focuses on clinical diabetes research. His research performs epidemiologic studies and clinical trials in the field of diabetes.

The research is focused on improving prognosis and evaluating suitable treatments to reduce the risk of complications for type 1 and 2 diabetes.

Dr Lind performs research evaluating which risk factors are associated with a lower mortality and risks of complications on the retina, kidneys, nerves and cardiovascular system. His group also focuses on understanding what persons are at risk for acute complications from diabetes. These studies are often of epidemiologic origin. As a complement the research group perform prospective studies and clinical trials to try to improve treatments in type 1 and type 2 diabetes. Essential fields are:

Screening studies to earlier detect complications
Diabetes Technology – e.g. of continuous glucose monitoring and insulin pumps
Psychologic interventions
Diet interventions
Glucose-lowering drugs in persons with type 1 and type 2 diabetes
Immunologic studies to preserve endogenous insulin production

Group members

Dr Lind is responsible for two diabetes clinical trial units. One at Sahlgrenska University Hospital/Östra, Gothenburg and one at the NU-Hospital Group, Uddevalla, Sweden.

PhD Students:

Earlier PhD students who have performed their PhD dissertations in the research group are:

Viktorija Anägnen Matuleviciene, Chief Physician at the Emergency Department of the Karolinska University Hospital, Stockholm, Sweden
Daniel Vestberg, Specialist Internal Medicine, NU-Hospital Group, Trollhättan and Uddevalla, Sweden

Current PhD students are:

Elsa Ahlén
Shilan Ahmadi
Sara Hallström
Sofia Sterner Isaksson
Arndís Finna Ólafsdóttir
Mauro Tancredi

Research Nurses and study coordinators

Marie Ekström, Sahlgrenska University Hospital/Östra and the NU-Hospital Group
Anna Folino, Sahlgrenska University Hospital/Östra and Sahlgrenska University Hospital/Mölndal

Research assistants:

Marianne Johansson, NU-Hospital Group
Daniel Pylov, University of Gothenburg

Medical Doctors assisting in clinical trials:

Lennart Kareld, senior consultant in internal medicine focusing on cardiology
Thomas Eriksson, senior consultant in internal medicine focusing on gastroenterology

The group has created a network of collaborations with data managers, monitors, logistics for laboratory handling, drug logistics and experienced statisticians for performing multicentre randomized clinical trials and epidemiologic studies. These are crucial close collaborators to the group for performing the research work.

Key Publications

Hallström S, Wijkman MO, Ludvigsson J, Ekman P, Pfeffer MA, Wedel H, Rosengren A, Lind M. Risk factors, mortality trends and cardiovasuclar diseases in people with Type 1 diabetes and controls: A Swedish observational cohort study. Lancet Reg Health Eur. 2022 Jul 22;21:100469. doi: 10.1016/j.lanepe.2022.100469. PMID: 35898332; PMCID: PMC9309414.
Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Diabetes Care. 2021 Jul 7:dc202439. doi: 10.2337/dc20-2439. Epub ahead of print. PMID: 34244332.
Lind M, Ólafsdóttir AF, Hirsch IB, Bolinder J, Dahlqvist S, Pivodic A, Hellman J, Wijkman M, Schwarcz E, Albrektsson H, Heise T, Polonsky W. Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI. Diabetes Care. 2021 Jan;44(1):141-149.
Lind M., Pivodic A., Svensson A-M., Ólafsdóttir AF., Wedel H., Ludvigsson J., HbA1c as a risk factor for retinopathy and nephropathy in persons with type 1 diabetes: Swedish Cohort study. BMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l4894
Vilsbøll T, Ekholm E, Johnsson E, Dronamraju N, Jabbour S, Lind M. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. Diabetes Care. 2019 Aug;42(8):1464-1472. doi: 10.2337/dc18-1988.
Dahlqvist S., Rosengren A., Gudbjornsdottir S., Pivodic A., Kosiborod M,Svensson A-M, Lind M. Risk of atrial fibrillation in persons with type 1 diabetes compared to matched controls from the general population - a prospective case-control study. Lancet Diabetes Endocrinol. 2017 Oct;5(10):799-807. doi: 10.1016/S2213-8587(17)30262-0
Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, Schwarz E, Ólafsdóttir AF, Frid A, Wedel H, Ahlén E, Nyström T, Hellman J. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA. 24;317(4):379-387. (2017)
Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjörnsdottir S, Wedel H, Clements M, Dahlqvist S, Lind M. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med. 373(18):1720-1732. (2015)
Lind M, Svensson AM, Kosiborod M, Gudbjörnsdottir S, Pivodic A, Wedel H, Dahlqvist S, Clements M, Rosengren A. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 371(21):1972-82. (2014)
Lind M, Hirsch IB, Tuomilehto J, Dahlqvist S, Ahrén B, Torffvit O, Attvall S, Ekelund M, Filipsson K, Tengmark BO, Sjöberg S, Pehrsson NG. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ. 351:h5364. (2015)
Lind M, Bounias I, Olsson M, Gudbjörnsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet. 378(9786):140-6. (2011)
Matuleviciene V, Joseph JI, Andelin M, Hirsch IB, Attvall S, Pivodic A, Dahlqvist S, Klonoff D, Haraldsson B, Lind M. A Clinical Trial of the Accuracy and Treatment Experience of the Dexcom G4 Sensor (Dexcom G4 System) and Enlite Sensor (Guardian REAL-Time System) Tested Simultaneously in Ambulatory Patients with Type 1 Diabetes. Diabetes Technol Ther. 16(11):759-67. (2014)
Lind M, Pivodic A, Cea-Soriano L, Nerman O, Pehrsson NG, Garcia-Rodriguez LA. Changes in HbA1c and frequency of measuring HbA1c and adjusting glucose-lowering medications in the 10 years following diagnosis of type 2 diabetes: a population-based study in the UK. Diabetologia. 57(8):1586-94. (2014)
Rosengren A, Svensson A-M, Kosiborod M, Pivodic A, Clements C, Gudbjörnsdottir S, Lind M. Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. Lancet Diabetes Endocrinol. 3(11):876-85. (2015)
Ólafsdóttir A.F., Attvall S., Sandgren U., Dahlqvist S., Pivodic A., Stanko S., Theodorsson E., Lind M. A clinical trial of the accuracy and treatment experience of the flash glucose monitor Free Style Libre in persons with type 1 diabetes. Accepted in Diabetes Diabetes Technol Ther. 19(3):164-172. (2017)
Olsson M, Schnecke V, Cabrera C, Skrtic S, Lind M. Contemporary Risk Estimates of Three HbA1c Variables for Myocardial Infarction in 101,799 Patients Following Diagnosis of Type 2 Diabetes. Diabetes Care. 38(8):1481-6. (2015)

Pågående aktiviteter hösten 2023

Tre studier kommer presenteras på EASD, Europeiska kongressen för diabetes i början av oktober.

Doktorand Sara Hallström disputerar.

Kliniska behandlingsstudier om kolhydratreducerad kost och CGM-behandling med distanssupport avslutas och sammanställs.

Rekrytering av patienter i studie om diabetesutbildad psykolog avslutas REDDIE-projektet initieras. En EU-studie där kardiovaskulära effekter av diabetesbehandlingar studeras.